In NSCLC, ALK is rearranged in approximately 3–7% of all patients [4–7], and in 20–30% of the subset of lung adenocarcinoma patients who are young and non-/light smokers [6–8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.